



These additions and changes are effective 12/12/25

Pharmacy Benefit Additions (these apply to Exchange only):

Vanrafia (atrasentan)– Pharmacy benefit, Non preferred brand, PA

Avmapki Fakzynja co-pack (avutometinib & defactinib) – Pharmacy benefit, Non preferred brand, PA

Ensacove (ensartinib) – Pharmacy benefit, Non preferred brand, PA

Ibtrozi (taletrectinib) – Pharmacy benefit, Non preferred brand, PA

Leqselvi (deuruxolitinib) – Pharmacy benefit, Non preferred brand, PA

Enflonsia (clesrovimab-cfor) – Pharmacy benefit, Non preferred brand, QL of one per lifetime

Andembry (garadacimab-gxii) – Pharmacy benefit, Non preferred brand, PA

Vyvgart Hytrulo PFS (Efgartigimod alfa and hyaluronidase) – Pharmacy benefit, Non preferred brand, PA

Leqembi IQLK (Lecanemab-irmb) – Pharmacy benefit, Non preferred brand, PA

Pharmacy Benefit Changes (these apply to Exchange only):

Wegovy (semaglutide) – Pharmacy benefit, Criteria update, New indication MASH

Medical Benefit Additions/Changes (these apply to Medicare and Exchange):

Enflonsia (clesrovimab-cfor) – Medical benefit

Andembry (garadacimab-gxii) – Medical benefit, PA

Lynozytic (linvoseltamab-gcpt) – Medical benefit, PA

Unloxcyt (cosibelimab-ipdl) – Medical benefit, PA

Avtozma (tocilizumab-anoh) – Medical benefit, PA